CollPlant Biotechnologies Ltd.

Welcome to the Coal Plant Biotechnologies Investor Conference Call to discuss financial results for the first quarter of 2023 and corporate updates. I'd now like to turn the call over to your host, Dori Kurowski of LifeSci Advisors. Please go ahead.

Good morning. I would like to welcome everyone to Coal Plant Biotechnologies Financial Results Conference Call for the first quarter ending March 31st, 2023. and corporate business update. With us on the call today from Coal Plant are Yahil Tal, Chief Executive Officer, who will provide an overview of the company's programs and forthcoming updates, and Aron Rotem, Deputy CEO and Chief Financial Officer, who will provide a summary of Coal Plant's financial results for the first quarter ending March 31st, 2023. Before we get started, I would like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of Coal Plant's filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on Coal Plant's website at www.coalplant.com. In addition, any forward-looking statements made on this call represent Coal Plant's views only as of today, May 24th, 2023, and should not be relied upon as representing the company's views as of any subsequent date. And Coal Plant Management specifically disclaims any obligation to update or revise any of these forward-looking statements. With that, let me turn the call over to Yehiel Tal, Chief Executive Officer of Coal Plant Biotechnologies. Please go ahead, sir.

Good morning, everyone. We are very pleased to have you join us today on Coal Plant Investor Conference call to discuss our first quarter 2023 financial results and corporate developments. Coal Plant is developing collagen technology and regenerative medicine products to improve and prolong lives. We are committed to becoming the leaders in regenerative medicine and supporting a more sustainable ecosystem that benefits all stakeholders, including patients, our shareholders, our employees, as well as providing innovation to the life science industry. At the heart of our business is our novel proprietary recombinant human collagen technology. Collagen is the building block for all human and mammalian tissues and serves as the primary scaffolding molecule in the body's connective tissues and organs. It is our goal to become a global leader in regenerative medicine by applying our non-animal derived recombinant human collagen or Rh collagen to novel medical anesthetics products. The hallmark of our technology, of course, is both its regenerative properties as well as that it is xeno-tissue-free. We are applying our technology to dermal filler product candidates for a long-term collaboration with our global pharmaceutical partner, AbbVie. The dermal filler candidates have the ability to shift the filler market since they would provide regenerative properties in addition to tissue filling. This program is our top focus, and it continues to move forward according to plan. CorePlan has the potential to receive additional milestones and option payments from AbbVie related to this program, as well as royalties on the dermal filler cells once this product candidate obtains approval. AbbVie continues to advance the filler program, and as stated previously, CorePlan expects that the first milestone could be achieved in 2023. Additionally, we continue to advance the development of state-of-the-art photocurable dermal and soft tissue filler. Our goal is to create an innovative filler product with three capabilities, lifting capacity, regeneration of new tissue, and contouring capabilities. As we are making these improvements to the filler products that exist today, we refer to this as a third generation filler. We believe that this filler has the potential to be highly competitive by providing both refined and natural looking aesthetic results, as well as uniquely regenerative long-term benefits. Furthermore, this technology could also be augmented to include facial and body contouring applications. Cortlandt has granted AbbVie the right of first negotiation to obtain a worldwide exclusive license to these product candidates. Now let's turn toward the regenerative breast implant program. At the beginning of this year, we announced positive results from the preclinical study evaluating our regenerative implants in a large animal model. We are very encouraged by these results, which demonstrated progressive stages of tissue regeneration after three months, as highlighted by the formation of maturing connective tissue and neovascular networks within the implants with no adverse events reported. This study forms the basis for our subsequent trial in the second large animal model, evaluating larger implants that we plan to initiate in the second half of this year. We are currently preparing the infrastructure to support this trial. No regenerative breast implant currently exists in the market, and these implants would be the first of their kind also having beneficial regenerative properties. Importantly, just recently in April, we announced a joint development and commercialization agreement with Stratasys a world leader in additive manufacturing and a leader in 3D printing technology after pioneering this technology decades ago. With Stratasys, we are collaborating on the development of a solution to biofabricate human tissues and organs. This collaboration combines the Stratasys DLP 3D printer that is utilizing a unique programmable photopolymerization P3 technology, together with Copeland state-of-the-art Rh-collagen-based bio-inks and 3D bioprinting capabilities. The first of our collaborative projects will focus on the development of an industrial scale solution for Copeland's regenerative breast implants program. An effective solution for scale-up of these implants will be important to support clinical trials and commercialization. Here you can see an example of a breast implant that was printed with Stratasys DLP 3D printer utilizing its P3 technology in combination with ColdPlant's RH collagen-based inks. Under the agreement, both companies have also agreed to cross-promote each other's bioprinted products. We do have strategic collaborations for bioprinting with multiple parties, and as we have said in the past, Our strategy is to utilize different printing technologies to serve different indications, being so, for example, a product that would need to have use of multiple materials or for the printing of constructs with very small features, such as gut-on-a-chip or lung-on-a-chip tissue models. The bioprinting aspect of our business has applicability in multiple areas. Cold plant implants are designed to regenerate breast tissue without eliciting immune response, and therefore have the potential to become a revolutionary alternative to both aesthetic and reconstructive procedures, including post-mastectomy for cancer patients. According to the US Food and Drug Administration, approximately 350,000 Americans have reported adverse events involving breast implants between 2009 and 2019. Reports range from autoimmune symptoms to breast implant-associated anaplastic loud cell lymphoma, or BIA-ALCL. The additional safety and efficacy data that we will generate from this study will be used for the optimization of the regenerative implant and are important in support for future regulatory submissions and clinical studies. We look forward to reporting these results from the study next year. Shifting to our Got on a Chip program, this is an area where we have the opportunity to disrupt the options that have traditionally existed in life sciences. Here, we are developing a diagnostic tool for use in personalized medicine And we expect that this approach could be groundbreaking improvement over the existing use of animal models for drug development. In November last year, we signed a collaboration agreement with Tel Aviv University and Chiba Medical Center for our Got on the Chip program. I should add that we are fortunate that the university and the medical centers are closed to us only 10 miles away, so we get to collaborate with our partners face-to-face quite frequently, enabling strong relationships. Our agreement with both institutions is to co-develop a bioprinted human intestine model for drug discovery and personalized treatment of ulcerative colitis. The 3D bioprinted model is designed to emulate the human intestine tissue in order to allow medical professionals to identify drug targets and personalized therapeutic responses that can lead to improved patient outcomes. Should a GAT on a chip receive approval, Cortland has exclusive rights to commercialize the product. Now, let me turn to our commercial portfolio of BioInks. This platform was established in 2021 with the launch of CoLink 3D50. Following this, We launched CoLink 3D90, which offers increased mechanical properties, and CoLink 3D50L, our first bioink available in powder form to provide enhanced operational flexibility. The entire platform allows our biopharma and academia customers to streamline their process of new product development by utilizing an animal-free alternative that delivers improved biofunctionality, safety, and reproducibility. ColdPlant remains engaged in partnering discussions with several additional industry leaders interested in ColdPlant technology and expertise in 3D bioprinting to develop therapeutics and medical applications. We have also developed a proprietary aseptic process to mass produce sterile Rh collagen. The sterile collagens that we are now producing will be utilized in our pipeline product as well as by our partners. Furthermore, it can serve as an ideal substrate for stem cells, induced pluripotent stem cells, and all kinds of primary human cells since our collagen will not elicit immune response and will accelerate cell proliferation. Finally, this collagen will also address production processes where collagen as a major constituent should be stirred. Now, I will turn the call over to our Deputy CEO and Chief Financial Officer, Eran Rotem, to provide a recap of the financial results.